drugset / Trial / NCT03588039
Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, Phase 1 dose-escalation study followed by a 2-arm expansion cohort of Oraxol administered in combination with pembrolizumab.
Timeline
- Start
- 2018-10-25
- Primary completion
- 2023-05-12
- Completion
- 2023-05-12
Outcome
Outcome not reported
Stopped (Business): “Study terminated due to lack of funding”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HM30181AK-US | Unknown | — | Oral |
| Subject | Paclitaxel | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |